Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
RNA-based vaccines were the heroes of the COVID-19 pandemic. They set records for the highest-grossing drug launches in history, and their development was recognized in this year’s Nobel Prize in Physiology or Medicine. But it was long known that this technology had a key shortcoming: RNA, in its usual linear form, is short-lived. Within hours, enzymes in cells descend on the molecule, chewing it to pieces. 
No comment yet.
Sign up to comment
Scoop.it!
Elon Musk is in Germany this week to discuss a collaboration with CureVac to build RNA microfactories, which could help vaccine development.
BigField GEG Tech's insight:
Elon Musk is looking to contribute Tesla’s tech resources to the battle against the coronavirus pandemic, again—despite having been dead wrong about the virus several times over the last five months. The cooperation between CureVac and Tesla’s Grohmann unit was first made public in July, when Musk tweeted that Tesla was looking into RNA microfactories “as a side project.”
|
Scoop.it!
BigField GEG Tech's insight:
A single dose of Johnson & Johnson's experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim results published on Friday.
|
Interesting article about the issue of RNA-based vaccines stability. Indeed rings of RNA could be a solution, but there are other strategies also promising and maybe more mature, such as VLPs delivering stable mRNAs or proteins.
By the way, GEG Tech will present in two weeks at the World Vaccine Congress very promising results about a new generation of nanoparticles delivering mRNA for vaccination, comprising and among other data about a very high protection against parasite in a Malaria animal model.